Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland

(Paris, France – 23^rd December 2025) – Curium, a world leader in nuclear medicine, has announced that patients in Poland received the first doses of PYLCLARI^® (INN: Piflufolastat (¹⁸F) also known as ¹⁸F-DCFPyL).

PYLCLARI^® is a diagnostic medicine used in adults to detect prostate cancer cells in patients with high-risk prostate cancer prior to initial curative therapy, and to localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.

Manufacturing and distribution of the product is managed by Curium’s new Partner Synektik Pharma Sp. z o.o.

Ciril Faia, CEO Curium International, said: “We are extremely pleased with today’s news that PYLCLARI^® is now available to patients with prostate cancer in Poland. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, the growing availability of PYLCLARI^® in Europe is improving the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose and monitor prostate cancer – ultimately for the benefit of patients with prostate cancer.”

Przemysław Kozanecki, CEO of Synektik Pharma, commented: ‘We are proud of our partnership with Curium and happy to be able to manufacture and supply PYLCLARI^® in Poland. Thanks to the expanding portfolio of Synektik’s products in the PET PSMA area, we will be offering a significant addition to the prostate cancer patients’ management.’

In Poland, prostate cancer is the most common cancer among men with around c.23,000 new cases diagnosed nationwide every year. Today’s announcement is part of the continued roll-out of PYLCLARI^® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, France, Spain, Austria, Germany, Belgium, Finland, Sweden, Czech Republic, Switzerland the Netherlands and now Poland.

In the U.S., Lantheus received approval for PYLARIFY^® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. In 2018, Curium received an exclusive license to develop and commercialize PYLCLARI® in Europe.